Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10807342	
Filing Date		2004-03-04	
First Named Inventor Bumi		man KIM et al.	
Art Unit		2817	
Examiner Name Krista		a M. Flanagan	
Attorney Docket Numb	er	1751-356	

				Altorn	ну БОС	ket mumber	1/31-330				
	U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Pate of cited Docu	entee or Applicant ment	Relev		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Relev		Lines where ges or Relev	
	1	20020191710	A1	2002-1	2-19	JECKELN et a	í.				
	2	20020018531	A1	2002-0	2-14	RATTO					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	ld buttor	n. Add		
				FOREIG	3N PA1	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code ²	Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	TE
	1										
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add		
	NON-PATENT LITERATURE DOCUMENTS Remove										

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		First Named Inventor Burnt Art Unit		man KIM et al. 2817			
		Examiner Name	Examiner Name Krista M. Flanagan				
				Attorney Docket Numb	er	1751-356	
	Examiner Initials*	Cite No		l, symposium, catalog, et		e article (when appropriate), title of the item te, pages(s), volume-issue number(s),	T5

Chinese Office Action with partial English translation, issued December 16, 2005 in the corresponding Chinese

10807342

2004-03-04

Application Number

Filing Date

INFORMATION DISCLOSURE

Application 200410032825.8

if you wish to add additional non-patent interactive document citation information please click the Add button						
EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a						

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reion of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		10807342	
FORMATION DIGGS COURT	Filing Date		2004-03-04	
FORMATION DISCLOSURE FATEMENT BY APPLICANT	First Named Inventor Bumman KIM et al		man KIM et al	
ot for submission under 37 CFR 1.99)	Art Unit		2817	
,	Examiner Name Krista M. Flanagan		ı M. Flanagan	
	Attorney Docket Numb	er	1751-356	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the app	ropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

OR

S

	That no item of information contained in the information disclosure statement was cited in a communication from a
	foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
\neg	after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
	any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
	-1-11

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/ Adam M. Treiber /	Date (YYYY-MM-DD)	2006-05-04
Name/Print	Adam M. Treiber	Registration Number	48000

This collection of information is required by 37 CFR. 187 and 1.98. The information is required to obtain or retain a benefit by the public which is to lie (and by the USFTO to process) an application. Confidentially is generate by \$5.U.S. CI 20 and 37 CFR. 11.4. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. Operatment of Commence, P. O. Box 1450, Alexandrin, V.S. 2231-1450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, VA 2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.